R Pauwels

Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial

Reinier C A van Linschoten, Fenna M. Jansen, R Pauwels et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 20 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +13

Ustekinumab Tissue and Serum Levels in Patients With Crohn’s Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction

Elisa Proietti, R Pauwels, C. Janneke van der Woude et al. · Inflammatory Bowel Diseases · 2022 · 17 citations · Full text

Veterinary Medicine, Clinical Sciences, Immunology +17

Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease

R Pauwels, Elisa Proietti, C. Janneke van der Woude et al. · Inflammatory Bowel Diseases · 2021 · 15 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Modulation of Indoleamine 2,3-Dioxygenase 1 During Inflammatory Bowel Disease Activity in Humans and Mice

Elisa Proietti, R Pauwels, Annemarie C. de Vries et al. · International Journal of Tryptophan Research · 2023 · 15 citations · Full text

Medicine, Immunology, Pharmacology +17

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease

R Pauwels, C. Janneke van der Woude, Nicole S. Erler et al. · Therapeutic Advances in Gastroenterology · 2020 · 13 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17